Clinical Trials Logo

Mucopolysaccharidosis II clinical trials

View clinical trials related to Mucopolysaccharidosis II.

Filter by:

NCT ID: NCT00004454 Completed - Clinical trials for Mucopolysaccharidosis II

Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)

Start date: October 1996
Phase: Phase 1/Phase 2
Study type: Interventional

OBJECTIVES: I. Evaluate the safety and feasibility of treating mucopolysaccharidosis II (mild Hunter syndrome) by lymphocyte gene therapy. II. Determine the levels of iduronate-2-sulfatase enzyme in these patients attained by infusing increasing doses of lymphocytes transduced with a retroviral vector designed for insertion and expression of this iduronate-2-sulfatase gene (L2SN). III. Determine the duration of survival of these transduced cells in these patients. IV. Determine whether monthly infusion of L2SN-transduced lymphocytes accomplishes metabolic correction (as measured by glycosaminoglycan excretion), decrease in liver or spleen volume, any therapeutic effect upon cardiac and pulmonary dysfunction, or any other effects from treatment.